Search All Jobs
Showing 20 of 207448 Jobs
Full-Time
Technical Product Manager
Software
Confirmed live in the last 24 hours
HeartFlow
501-1,000 employees
Non-invasive cardiac testing for heart disease
Compensation Overview
$95k - $160k/yr
Junior, Mid
Mountain View, CA, USA
Upload your resume to see how it matches 9 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
- Outstanding communication skills, both written and oral
- Proven ability to handle ambiguity, work collaboratively with internal and partner contacts, and influence cross-functional teams.
- Strong technical aptitude
- Direct experience with scrum methodologies for product development and delivery
- Highly productive with exceptional organizational capacity
- Ability to translate technical designs to written requirements
- Demonstrated passion for problem solving
- Bachelor’s degree or higher preferably in engineering (software preferred)
- 1-3 years of experience in Product Management or similar experience in medical product development
- Solid technical understanding of all aspects of the product for generating requirements and facilitating communication between teams
- Drive design of features by defining Use Cases and Workflows
- Write high quality functional requirements and coordinate design reviews for cross-functional understanding and approval
- Set scope and requirements that are aligned to product and business strategy
- Manage traceability of product requirements to market requirements and user needs
- Work with developers to implement requirements
- Evaluate and provide feedback on prototypes or builds
- Assess patient safety risk and identify design mitigations
- Champion regulatory standards and manage constraints
- Conduct usability tests and compose reports for internal users
- Manage prioritization of defects by understanding their impact to the product
- Be the content expert for our Instructions For Use
- Understand and prioritize user feedback
HeartFlow provides a non-invasive cardiac test that helps visualize a patient's coronary arteries, aiding physicians in diagnosing and treating heart disease. The technology allows for detailed imaging without the need for invasive procedures, which reduces risks for patients and lowers costs for healthcare providers. HeartFlow's main product, the HeartFlow Analysis, includes various analyses such as FFRCT, RoadMap, and Plaque Analysis, and has received FDA clearance, making it available in the U.S., U.K., Japan, and Canada. Unlike competitors, HeartFlow focuses on providing a safer and more efficient diagnostic tool for cardiovascular care. The company's goal is to enhance treatment planning for heart disease while generating revenue through the sale of its technology and related services.
Company Size
501-1,000
Company Stage
N/A
Total Funding
$990.6M
Headquarters
Redwood City, California
Founded
2010
Simplify's Take
What believers are saying
- HeartFlow secured $98M funding to advance its AI-driven coronary care platform.
- The company launched the GAMEFILM Registry to study heart health in retired NFL players.
- HeartFlow's new CPT code for AI-enabled Plaque Analysis enhances its diagnostic capabilities.
What critics are saying
- Emerging AI-driven cardiovascular diagnostic companies could threaten HeartFlow's market share.
- Algorithmic bias in AI models poses a risk of inaccurate diagnoses for HeartFlow.
- Rapid technological advancements could render HeartFlow's current technology obsolete.
What makes HeartFlow unique
- HeartFlow offers a unique non-invasive cardiac test using AI-driven FFRCT Analysis.
- The company provides comprehensive coronary artery visualization, combining anatomy, physiology, and plaque analysis.
- HeartFlow's technology is FDA-cleared and commercially available in major global markets.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Stock Options
401(k) Company Match
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↓ -2%Heartflow, Inc. announced a $98 million convertible notes financing led by its parent company, Heartflow Holding, Inc. New and existing investors, including Fidelity Management, Janus Henderson, and Bain Capital, participated. The funds will support R&D to advance Heartflow's AI-driven coronary care platform. Heartflow's technology, recognized for innovation, aims to improve CAD diagnosis and management. The platform has been used for over 400,000 patients globally.
Heartflow was recently named one of Fast Company's Most Innovative Companies in Medical Devices for 2025 and won the Innovation in Cardiac Imaging award at the Global Cardiovascular Awards 2025.
HeartFlow and Boone Heart Institute Launch GAMEFILM Registry to Study Heart Health in Retired NFL Players. by Fred Pennic 01/22/2025 Leave a Comment. What You Should Know: – HeartFlow, a global leader in AI-driven heart care solutions, and Boone Heart Institute, a renowned cardiovascular care provider in Denver, today announced the launch of the GAMEFILM Registry. – GAMEFILM Registry will utilize advanced imaging and AI technology to assess and better understand coronary artery disease (CAD) risk in retired National Football League (NFL) players.Understanding the Unique Cardiovascular Risks of Retired NFL PlayersCardiovascular disease remains the leading cause of death globally. Despite advancements in diagnostics, many heart attacks and strokes occur in individuals without prior symptoms. Early identification of high-risk individuals is critical for effective prevention and treatment. Retired NFL players often face unique cardiovascular health challenges due to the intense physical demands of their careers
HeartFlow announces new Category I CPT code from the American Medical Association for ai-enabled Plaque Analysis to assess risk for coronary artery disease.
HeartFlow launches plaque analysis platform for coronary artery disease.